Impact of differential glycemic management goals in pre-anhepatic and anhepatic phase on early grafted liver function after liver transplantation: An open-label, randomized, controlled study
Primary resultResult — go to the resultRelative risk 0.32 95 % CI 0.110–0.562Authors' conclusion
Adopting LIGM (7.8-10.0 mmol/L) during the pre-anhepatic and anhepatic phases helps to reduce the incidence of EAD after LT and promotes the recovery of liver function, but does not increase the incidence of postoperative infections.
Study context
- Population
- Adult liver transplantation recipients182 completed
- Participants
- 188 recipients
- Comparison
- Less intensive glucose management (LIGM) vs more intensive glucose management (MIGM)
- LIGMn = 89
- MIGMn = 93reference
- Primary endpoint
- Early allograft dysfunction (EAD)
Methodological detailsopen-label, prospective, 1:1 allocation
- Open-label
- Prospective
- 1:1 allocation
Primary result
As reported in the abstract
Relative risk
0.32
95 % CI 0.110–0.562
P < 0.001
By group
LIGM vs MIGM
RR 0.32 (95 % CI 0.110–0.562); P < 0.001
Secondary outcomes
One-year survival
P = 0.044
Safety
| Outcome | P value |
|---|---|
| 30-day postoperative infection | P > 0.05 |
30-day postoperative infection
- No statistical difference between the two groups
Original publication
Impact of differential glycemic management goals in pre-anhepatic and anhepatic phase on early grafted liver function after liver transplantation: An open-label, randomized, controlled study. J Clin Anesth. Published 15 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →